Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: Results of the prospective AML96 trial

Leukemia

Volumn 25, Issue 3, 2011, Pages 420-428

  Stolzel F ^a   Pfirrmann, M ^b   Aulitzky, W E ^c   Kaufmann, M ^c   Bodenstein, H ^d   Bornhauser M ^a   Rollig C ^a   Kramer, M ^a   Mohr, B ^a   Oelschlagel U ^a   Schmitz, N ^e   Soucek, S ^a   Thiede, C ^a   Ehninger, G ^a   Schaich, M ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c ROBERT BOSCH HOSPITAL   (Germany)

^d KLINIKUM MINDEN   (Germany)

^e DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

prognostic score; risk stratification; secondary AML

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; EVENT FREE SURVIVAL; GENE MUTATION; HIGH RISK POPULATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL TIME; THROMBOCYTE COUNT; VALIDATION STUDY;

EID: 79952449648     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.279     Document Type: Article

References (38)

1. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica 1999; 84: 937-945. . (Pubitemid 29516926)
2. Mufti GJ. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Pract Res Clin Haematol 2004; 17: 543-557. . (Pubitemid 39378186)
3. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323-3329. .
4. Mauritzson N, Albin M, Rylander L, Billstrom R, Ahlgren T, Mikoczy Z et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002; 16: 2366-2378. . (Pubitemid 36067289)
5. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894-1907. . (Pubitemid 44794525)
6. Rund D, Krichevsky S, Bar-Cohen S, Goldschmidt N, Kedmi M, Malik E et al. Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia 2005; 19: 1919-1928. . (Pubitemid 41554000)
7. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145: 598-605. .
8. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2005; 128: 324-332. . (Pubitemid 40216154)
9. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159. . (Pubitemid 17064313)
10. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335. . (Pubitemid 34627197)
11. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011-4020. . (Pubitemid 43726809)
12. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649. . (Pubitemid 46594039)
13. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519-1538. . (Pubitemid 32202560)
14. Wandt H, Ehninger G, Gallmeier WM. New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist 2001; 6: 446-450. . (Pubitemid 33022216)
15. Krauter J, Wagner K, Schafer I, Marschalek R, Meyer C, Heil G et al. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2009; 27: 3000-3006. .
16. Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006; 108: 3280-3288. .
17. Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27: 61-69. .
18. Ferrara F, Criscuolo C, Riccardi C, Izzo T, Pedata M, Copia C et al. FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype. Am J Hematol 2009; 84: 532-535. .
19. Borowitz MJ, Gockerman JP, Moore JO, Civin CI, Page SO, Robertson J et al. Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia. Am J Clin Pathol 1989; 91: 265-270. . (Pubitemid 19074534)
20. Solary E, Casasnovas RO, Campos L, Bene MC, Faure G, Maingon P et al. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR-phenotypes with shorter survival. Groupe d0Etude Immunologique des Leucemies (GEIL). Leukemia 1992; 6: 393-399. .
21. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-1320. .
22. Schlenk RF, Dohner K, Kneba M, Gotze K, Hartmann F, Del Valle F et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009; 94: 54-60. .
23. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088. . (Pubitemid 27132124)
24. Germing U, Platzbecker U, Giagounidis A, Aul C. Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes. Br J Haematol 2007; 138: 399-400. . (Pubitemid 47035388)
25. Kao JM, McMillan A, Greenberg P. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008; 83: 765-770. .
26. Pagano L, Pulsoni A, Vignetti M, Tosti ME, Falcucci P, Fazi P et al. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. Ann Oncol 2005; 16: 228-233. . (Pubitemid 40309301)
27. Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M et al. Survival of elderly patients with acute myeloid leukemia. Haematologica 2004; 89: 296-302. . (Pubitemid 38788413)
28. Ferrara F, Fazi P, Venditti A, Pagano L, Amadori S, Mandelli F. Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell0 Adulto (GIMEMA) Acute Leukaemia Working Party. Haematol Oncol 2008; 26: 104-107. . (Pubitemid 351951339)
29. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266. . (Pubitemid 40110814)
30. Andersen MT, Andersen MK, Christiansen DH, Pedersen-Bjergaard J. NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features. Leukemia 2008; 22: 951-955. . (Pubitemid 351689876)
31. Lo-Coco F, Cuneo A, Pane F, Cilloni D, Diverio D, Mancini M et al. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. Haematologica 2008; 93: 1017-1024. . (Pubitemid 351965466)
32. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008; 22: 240-248. . (Pubitemid 351250527)
33. Falini B. Therapy-related acute myeloid leukaemia with mutated NPM1: treatment induced or de novo in origin? Leukemia 2008; 22: 891-892. . (Pubitemid 351689872)
34. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007; 109: 874-885. . (Pubitemid 46220630)
35. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106: 3740-3746. . (Pubitemid 41739007)
36. Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 2009; 23: 1731-1743. .
37. Scholl S, Theuer C, Scheble V, Kunert C, Heller A, Mugge LO et al. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Eur J Haematol 2008; 80: 208-215. . (Pubitemid 351253464)
38. Löwenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Am Soc Hematol Educ Program 2008; 1: 1-11.